<DOC>
	<DOC>NCT00175955</DOC>
	<brief_summary>An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia</brief_summary>
	<brief_title>Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Dyskinesia, Drug-Induced</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Subjects between ages 18 and 80 years Subjects must have a diagnosis of stable axis I psychiatric disorder at least 6 months prior to screening Subjects must have a stable neurolepticinduced tardive dyskinesia at least 1 month prior to screening and meet tardive dyskinesia severity criteria Subjects must have used antipsychotics for at least 6 cumulative months, and, be on a stable dose for 1 month prior to screening Presence of any axis II condition within 6 months prior to screening Huntington´s disease, idiopathic dystonia, Wilson´s disease, Sydenham´s chorea, thyroid dysfunction, spontaneous dyskinesia Start of drugsother than neuroleptics that can cause dyskinesia Presence of additional major disease such as cardiac, renal or hepatic dysfunction or terminal illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Neuroleptic-induced tardive dyskinesia</keyword>
	<keyword>Keppra, Levetiracetam</keyword>
</DOC>